UCL
8.9.2021 10:03:32 CEST | Business Wire | Press release
University College London (UCL), a top-10 globally ranked university, has published a significant new research paper on the varying environmental impacts of different distributed ledger technologies (DLT). The paper examined the energy consumption of second-generation consensus models such as Proof-of-Stake, which promise to provide more favourable energy consumption characteristics than their Proof-of-Work predecessors. Researcher’s at UCL’s Centre for Blockchain Technologies (UCL CBT) quantified and compared the energy demands of six second-generation systems: Algorand, Cardano, Ethereum 2.0, Hedera Hashgraph, Polkadot, and Tezos. The full paper can be found here .
The research paper found that Hedera Hashgraph had the lowest overall energy consumption of the systems studied. Dr. Paolo Tasca, Executive Director at UCL CBT, said: “At this point, the benefits of Proof-of-Stake are well-recognised and understood in the blockchain space. However, through this research we have found that not all Proof-of-Stake networks are created equally. This is something that both investors and adopters need to be wary of when selecting their network of choice. While it’s fantastic to see that Ethereum 2.0 will be Proof-of-Stake, looking at these results it’s clear that we need to remain vigilant of its potential environmental impact.”
The research was conducted by UCL CBT by formalizing a basic mathematical consumption model for validator-based Sybil attack resistance schemes. This model allows quantifying the energy consumption per transaction based on common input variables, such as the number of validators and the throughput characteristics of the system analysed.
Ultimately, the study found that the energy needs of the varying consensus protocols was dependent on the number of active validators. The UCL researchers warned that distributed ledger technology (DLT) networks need to be wary of the effect of different design choices in their architecture over energy consumption, as well as of the quality of the hardware used by the node operators. The research concluded that DLT networks must remain focused on environmental friendliness as scale increases.
Dr. Tasca concluded: “The findings of this study are a fantastic starting point for improving existing DLT design options, as well as developing new consensus protocols while keeping sustainability front of mind. We found that, through applying contemporary throughput and validator counts, Hedera Hashgraph has the most favourable energy consumption characteristics.”
For more information, download the full report at: http://blockchain.cs.ucl.ac.uk/blockchain-energy-consumption/
About University College London
Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 13,000 staff and 42,000 students from 150 different countries. Ranked 8th in the world by QS World University Rankings in 2022, University College London is amongst the best universities in the world. It was the first university in England to welcome students of any religion and the first to welcome women on equal terms with men. UCL's founding principles of academic excellence and research aimed at addressing real-world problems continue to inform its ethos to this day through focusing its research endeavours on the Grand Challenges of Global Health, Sustainable Cities, Cultural Understanding, Human Wellbeing, Transformative Technology, and Justice & Equality. UCL’s dedication to world-class research, education and innovation is recognised through its globally recognised ranking. In the most recent Research Excellence Framework, UCL was the top-rated university in the UK for research strength.
About the UCL Centre for Blockchain Technologies (UCL CBT)
UCL CBT is the world’s largest research centre on blockchain technologies by number of associates. Founded in 2015 by Prof. Paolo Tasca and Prof. Tomaso Aste, its mission is to research the effects of Distributed Ledger Technologies and Blockchain into our socio-economic systems and to promote the safe and organic development and adoption of Blockchain-based platforms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005169/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom